全文获取类型
收费全文 | 2544篇 |
免费 | 123篇 |
国内免费 | 75篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 183篇 |
妇产科学 | 26篇 |
基础医学 | 252篇 |
口腔科学 | 59篇 |
临床医学 | 267篇 |
内科学 | 539篇 |
皮肤病学 | 201篇 |
神经病学 | 147篇 |
特种医学 | 402篇 |
外科学 | 193篇 |
综合类 | 46篇 |
预防医学 | 97篇 |
眼科学 | 96篇 |
药学 | 111篇 |
2篇 | |
肿瘤学 | 119篇 |
出版年
2021年 | 12篇 |
2020年 | 19篇 |
2019年 | 17篇 |
2018年 | 36篇 |
2017年 | 23篇 |
2016年 | 24篇 |
2015年 | 43篇 |
2014年 | 49篇 |
2013年 | 68篇 |
2012年 | 43篇 |
2011年 | 56篇 |
2010年 | 94篇 |
2009年 | 92篇 |
2008年 | 62篇 |
2007年 | 98篇 |
2006年 | 61篇 |
2005年 | 67篇 |
2004年 | 38篇 |
2003年 | 30篇 |
2002年 | 43篇 |
2001年 | 55篇 |
2000年 | 45篇 |
1999年 | 39篇 |
1998年 | 136篇 |
1997年 | 157篇 |
1996年 | 138篇 |
1995年 | 112篇 |
1994年 | 115篇 |
1993年 | 99篇 |
1992年 | 43篇 |
1991年 | 37篇 |
1990年 | 48篇 |
1989年 | 67篇 |
1988年 | 56篇 |
1987年 | 56篇 |
1986年 | 60篇 |
1985年 | 57篇 |
1984年 | 35篇 |
1983年 | 26篇 |
1982年 | 37篇 |
1981年 | 41篇 |
1980年 | 36篇 |
1979年 | 22篇 |
1978年 | 28篇 |
1977年 | 32篇 |
1976年 | 33篇 |
1975年 | 32篇 |
1974年 | 23篇 |
1973年 | 22篇 |
1968年 | 11篇 |
排序方式: 共有2742条查询结果,搜索用时 15 毫秒
1.
JM Martín† L Calduch† C Monteagudo‡ I Molina† D Ramón† V Alonso† E Jordᆠ《Journal of the European Academy of Dermatology and Venereology》2006,20(4):428-431
Cutaneous plasmacytosis is a rare disorder characterized by a benign proliferation of mature plasma cells that appears as multiple dark-brown to purplish skin lesions, often associated with polyclonal hypergammaglobulinaemia. We present the case of a 55-year-old Caucasian man who suffered from a cutaneous plasmacytosis associated with two different carcinomas. Cutaneous plasmacytosis seems to be a reactive process because most cases reported are not associated with any apparent underlying disease. Nevertheless, because few reported cases were associated with malignancies, screening of additional neoplasms would be justified. 相似文献
2.
H. S. Pollinger M. D. Stegall J. M. Gloor S. B. Moore S. R. Degoey N. A. Ploeger W. D. Park H. S. Pollinger M. D. Stegall J. M. Gloor S. B. Moore S. R. Degoey N. A. Ploeger W. D. Park 《American journal of transplantation》2007,7(4):857-863
The immunologic risk associated with donor-specific antibodies (DSA) against Class II human leukocyte antigens (HLA) in kidney transplant (KTx) recipients is unclear. The aim of this study was to determine the outcome of KTx when DSA was detected only against HLA Class II. To isolate the impact of anti-Class II DSA, we retrospectively analyzed 12 KTx recipients who at baseline had a positive B-cell flow cytometric crossmatch (FXM) and a negative T-cell FXM. Using alloantibody specification analysis, 58.3% (7/12) had DSA against donor Class II and 41.7% had no demonstrable DSA. Biopsy-proven AMR occurred in 57% (4/7) in the Class II(+) group and 0% in the Class II(-) group (p > 0.05). Peritubular capillaries stained positive for C4d in 86% (6/7) of the Class II(+) patients and in 40% (2/5) of the Class II(-) patients (p > 0.05). One patient in the Class II(+) group lost their graft at 3 months to accelerated transplant glomerulopathy, while all other grafts were functioning 3-37 months posttransplant despite the persistence of anti-Class II DSA. We conclude that KTx recipients with clearly defined anti-Class II DSA are at risk for humoral rejection suggesting that desensitization and/or close posttransplant monitoring may be needed to prevent AMR. 相似文献
3.
JM Vilanova J Figueras-Aloy J Roselló G Gómez E Gelpí R Jiménez 《Acta paediatrica (Oslo, Norway : 1992)》1998,87(5):588-592
The aim of this study was to evaluate the cerebral synthesis of eicosanoids in the asphyctic newborn and to investigate the relation between the prostanoid profiles in cerebrospinal fluid (CSF) and the appearance and severity of hypoxic-ischaemic encephalopathy (HIE). Levels of 6-keto-PGF 1-α, TXB2 , PGE2 and PGF2-α in CSF were measured in 40 full term newborns during the first day of life. Thirty of these newborns had birth asphyxia and were divided into three groups: 10 without HIE, 12 with mild HIE and 8 with moderate-severe HIE. They were compared to a control group of 10 non-hypoxic newborns. Determinations of the metabolites in CSF were performed by RIA and expressed as pg/ml (mean ± SD). The CSF TXB2 (thromboxane A2 metabolite) in asphyxiated newborns was always higher than in the control group (28.12 ± 10.6), and related to the severity of HIE ( p = 0:005): without HIE (50.84 ± 16.4; p = 0:02), mild HIE (80.65 ± 12.64; p ± 0:01) and moderate-severe HIE (178.14 ± 20.5; p < 0:01). The CSF 6-keto-PGF 1-α (prostacyclin metabolite) in asphyxiated newborns was always higher than in the control group (80.55 ± 12.56), but indirectly related to the severity of HIE: without HIE (240.95 ± 28.12; p < 0:01), mild HIE (183.65 ± 30.1; p < 0:01) and moderate-severe HIE (140.55 ± 25.12; p < 0:01). In the moderate-severe HIE group, the increase in TXB2 was higher than the rise in 6-keto-PGF 1-α . 相似文献
4.
5.
6.
M. Myslak H. Amer P. Morales M. E. Fidler J. M. Gloor T. S. Larson M. D. Stegall F. G. Cosio 《American journal of transplantation》2006,6(7):1660-1665
Increasing numbers of patients receive kidney transplants before initiation of dialysis or shortly thereafter. Some of these patients have significant proteinuria pre-transplant making the interpretation of post-transplant proteinuria problematic. In this study, we evaluated post-transplant proteinuria in 115 patients who had urine protein measured within 3 months of transplant and assessed the association of proteinuria with allograft pathology. Proteinuria declined rapidly from 3650 +/- 3702 mg/day pre-transplant to 550 + 918 at 3 weeks (p < 0.0001) and continued to decline until 1 year post-transplant (472 +/- 1116, p < 0.0001 vs. 3 weeks). Proteinuria greater than 3000 mg/day was present in 48 patients (42%) pre-transplant, in 1 patient (1%) at 3 weeks and in 4 patients (4%) at 1 year. Surveillance graft biopsies were done at 1 year in 93% of patients. Proteinuria > or = 1500 mg/day and/or an absolute increase in proteinuria > 500 mg/day after 3 weeks post-transplant was associated with allograft glomerular pathology. In conclusion, pre-transplant proteinuria, even when high grade, declines rapidly after transplantation. Failure to decline or persistence of proteinuria greater than 1500 mg/day is indicative of allograft pathology. 相似文献
7.
8.
9.
10.